Blackhawks drop Capitals to 0-5 in shootouts, beat Washington in 6 rounds for a 3-2 win

WASHINGTON (AP) — Nick Foligno scored in the sixth round of a shootout to give the Chicago Blackhawks a 3-2 victory over the Washington Capitals on Saturday night.

The Capitals fell to 0-5 in shootouts this season. Sonny Milano gave Washington a brief lead when he scored in the fifth round, but former Capitals forward Andre Burakovsky tied it for the Blackhawks. Then Jakob Chychrun failed to score for Washington and Foligno ended it.

Ryan Donato and Teuvo Teravainen scored for Chicago in regulation, and Dylan Strome and Ryan Leonard scored for the Capitals. Leonard tied it with 8:42 left in the third period.

The Capitals lost forward Tom Wilson, who was picked earlier in the week for Canada’s Olympic team, in the first period to an apparent leg injury. Washington was also without forward Aliaksei Protas because of a lower-body injury.

The Blackhawks have won back-to-back games for the first time since mid-November. Washington earned points in 13 of 14 games from Nov. 15 through Dec. 11, but the Capitals are just 3-6-2 since.

This was Washington’s first meeting with Chicago since April 4, when Alex Ovechkin scored twice against the Blackhawks to tie Wayne Gretzky’s career record of 894.

Donato opened the scoring after just 73 seconds in the first period when he tipped in a shot by Ilya Mikheyev. Strome answered when he put away a rebound off a shot by Ethen Frank.

Teravainen flipped the puck over sprawling goalie Logan Thompson on a second-period power play for a 2-1 lead.

Blackhawks: Host Vegas on Sunday.

Capitals: Host Anaheim on Monday night.

AP NHL: https://apnews.com/hub/NHL

Washington Capitals left wing Alex Ovechkin (8) looks on during the first period of an NHL hockey game against the Chicago Blackhawks, Saturday, Jan. 3, 2026, in Washington. (AP Photo/Nick Wass)

Washington Capitals center Dylan Strome (17) celebrates his goal with center Ethen Frank (53) and defenseman Trevor van Riemsdyk (57) during the first period of an NHL hockey game against the Chicago Blackhawks, Saturday, Jan. 3, 2026, in Washington. (AP Photo/Nick Wass)

Washington Capitals right wing Tom Wilson (43) grimaces and is slow to get up after being injured during the first period of an NHL hockey game against the Chicago Blackhawks, Saturday, Jan. 3, 2026, in Washington. (AP Photo/Nick Wass)

Chicago Blackhawks center Teuvo Teravainen (86) celebrates after his goal during the second period of an NHL hockey game against the Washington Capitals, Saturday, Jan. 3, 2026, in Washington. (AP Photo/Nick Wass)

NEW YORK--(BUSINESS WIRE)--Jun 1, 2026--

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601532429/en/

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the study design for the Company’s Phase 3 PROSERA study, particularly, controlling for the placebo response at the Latin American testing sites.

On February 23, 2026, Gossamer Bio, Inc. revealed adverse topline results from its Phase 3 PROSERA study, announcing that the trial failed to meet its primary endpoint of improving six-minute walk distance (“6MWD”) at Week 24. While the study reported a placebo-adjusted gain of +13.3 meters, the result did not achieve statistical significance under the prespecified alpha threshold of 0.025 (p=0.0320). The Company attributed the outcome, in part, to unexpectedly strong placebo performance among patients enrolled at Latin American sites, which it characterized as a heavily treated, lower-risk population.

Following this disclosure, investors and analysts reacted swiftly and negatively. On February 23, 2026, Gossamer’s common stock price plummeted from a closing price of $2.13 per share on February 20, 2026 to $0.42 per share, representing a decline of more than 80% in a single trading day.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Gossamer’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Gossamer Bio class action, go to www.faruqilaw.com/GOSS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline